Consolidated experience leading research projects with multiple stakeholders, from a very diverse range of environments and countries.
Proven track record on
highly innovative research projects
DARWIN EU®: Data Analysis and Real World Interrogation Network
The European Medicines Agency (EMA) is establishing a Coordination Centre to provide timely and reliable evidence on the use, safetyand effectiveness of medicines for human use, including vaccines, from realworld healthcare databases across the European Union (EU). The role of the Coordination Centre is to develop and manage a network of real-world healthcare data sources across the EU and to conduct scientific studies requested by medicines regulators and, at a later stage, also requested by other stakeholders. By supporting decision-making on medicines, a wide range of stakeholders will benefit, from patients and healthcare professionals to health technology assessment bodies, payers and the pharmaceutical industry. Additionally, DARWINEU® will provide an invaluable resource to prepare for and respond to future healthcare crises and pandemics.
EHDEN: European Health Data & Evidence Network
The mission of the European Health Data & Evidence Network (EHDEN) is to provide a new paradigm for the discovery and analysis of health data in Europe, by building a large-scale, federated network of data sources standardised to a common data model. EHDEN will build on prior projects, such as EMIF and EHR4CR, in scaling their original intents and technologies.
NEURONET: Efficiently Networking European Neurodegeneration Research
The main aim of NEURONET is to set up an efficient platform to boost synergy and collaboration across the IMI projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility, and facilitating dovetailing with related initiatives in Europe and worldwide.
Neuronet KB includes links to over 380 publications and more than 350 publishable deliverable report
This comprehensive resource is an integral part of NEURONET's endeavour to boost collaboration across the research portfolio by assisting in identifying gaps, multiplying the portfolio's impact and enhancing its visibility with related initiatives in Europe and worldwide.
ERA4TB: European Accelerator of Tuberculosis Regime
ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative devoted to accelerating the development of new treatment regimens for tuberculosis. The ERA4TB platform is based on a progression pipeline that can cater simultaneously for a variety of molecules at different stages of development.
TransBioLine: Translational Safety Biomarker Pipeline Project
The Translational Safety Biomarker Pipeline (TransBioLine) Project aims to generate exploratory and confirmatory data supporting regulatory qualification and acceptance of novel safety biomarkers for five target organ systems (kidney, liver, pancreas, vascular, and central nervous system) for application in drug development.
Interactive dashboard to aid Project Coordinators in the tracking of the overall status of collaborative research projects
SYNAPSE PI is a graphical interface based on the Business Intelligence dashboard model, that displays key documentation, metrics and day-to-day relevant information at a single glance.
HTx: Next Generation Health Technology Assessment
The overall objective of HTx is to create a framework for next generation Health Technology Assessment that supports patient-centred, societally oriented, real-time decision-making for integrated healthcare throughout Europe.
eTRANSAFE: Enhancing Translational Safety Assessment Through Integrative Knowledge Management
The eTRANSAFE project aims at improving the safety assessment across the drug discovery and development process by applying bioinformatics approaches to shared preclinical and clinical data to systematically analyse the translatability of effects. Thus, enabling the optimisation of resources and the development of safer medicines.
ROADMAP: Real world Outcomes across the Alzheimer’s Disease spectrum for better care: Multi-modal data Access Platform
ROADMAP aims to create the conditions for an open collaboration that yields consensual and efficient uses of RWE for the benefit of Alzheimer’s Disease patients and their caregivers. This will be achieved by using pilot studies to assess methods of data integration for patient outcomes that are useful for disease modelling; and developing tools and methods for stakeholder engagement. ROADMAP will set new standards for the collation and evaluation of RWE in Alzheimer’s Disease.
3D interactive cube that allows the visualisation of the landscape on available Alzheimer's disease data in Europe.
This tool consists of a data cube that can be seen as a tree-dimensional “heat map” to interactively visualise how European data sources captures relevant AD-related outcomes. It also provides an overview of the relevance of such outcomes for different disease stages, and for different types of stakeholders.
DRIVE: Developments of Robust and Innovate Vaccine Effectiveness
DRIVE aims at developing a governance model between public and private entities to enable a sustainable network of influenza vaccine effectiveness. This model will ensure scientific independence in the studies and full transparency, allowing different stakeholders to fulfil their needs considering their respective obligations and statutes.
TransQST: Translational Quantitative Systems Toxicology
TransQST aims to develop novel computational approaches using the best available data from the public and private domains to improve the understanding of adverse drug reactions (i.e., unwanted side effects of medication) to reduce significantly patient morbidity, mortality and hospitalisation costs.
HARMONY: Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hematology
HARMONY aims at capturing, integrating, analysing, and harmonising anonymous patient data from high-quality multidisciplinary sources to unlock valuable knowledge on haematological diseases for a better prognosis and quicker life-saving decisions for patients.
AMYPAD: Amyloid imaging to prevent Alzheimer’s Disease
AMYPAD aims at studying the onset, dynamics, and clinical relevance of brain β-amyloid in the spectrum from normal ageing, through subjective cognitive decline towards mild cognitive impairment and ultimately dementia due to Alzheimer’s Disease (AD), studying the value of β-amyloid imaging as a diagnostic and therapeutic marker for AD.
EPAD: European Prevention of Alzheimer’s Dementia
EPAD aims to develop an infrastructure that efficiently enables the undertaking of adaptive, multi-arm Proof of Concept studies for early and accurate decisions on the ongoing development of drug candidates or drug combinations.
